TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07617337: AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Sponsor: Chugai Pharmaceutical · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 102 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$5,843,376

Rescue Site Savings

+$3,864,168

Unlock Full NCT07617337 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07617337 Rescue Dossier →